---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-277521"
form_type: "8-K"
ticker: "BOLT"
cik: "0001641281"
company_name: "Bolt Biotherapeutics, Inc."
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T21:15:32.370415+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Bolt Biotherapeutics Q3 2025: operating loss $7.7M, cash $38.8M; BDC-4182 data expected 3Q26

## Summary
- Collaboration revenue $2.2M (vs $1.1M Q3 2024); R&D expenses $6.5M (down 53% YoY).
- Operating loss $7.7M vs $16.4M YoY, reflecting restructuring and discontinuation of BDC-1001.
- Cash and securities $38.8M as of Sep 30, 2025; runway into 2027.
- Initial Phase 1 data for BDC-4182 (claudin 18.2 ISAC) expected 3Q2026.
- Presented preclinical data for next-gen CEA and PD-L1 ISACs at SITC; seeking partner for BDC-3042.

## SEC filing metadata
- accession: 0001193125-25-277521
- form_type: 8-K
- ticker: BOLT
- cik: 0001641281
- company_name: Bolt Biotherapeutics, Inc.
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641281/000119312525277521/0001193125-25-277521-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641281/000119312525277521/bolt-20251112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-277521
- JSON: https://secwatch.observer/filing/0001193125-25-277521.json
- Plain text: https://secwatch.observer/filing/0001193125-25-277521.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.